Week 21
Background:
In the double-blind, phase 3 KEYNOTE-189 study (NCT02578680), pembrolizumab+pemetrexed+platinum significantly improved OS and PFS over placebo+pemetrexed+platinum as first-line therapy for non-squamous NSCLC. Grade 3-5 drug-related AE rates were higher with pembrolizumab. These PRO results were previously presented at the ASCO Annual Meeting in Chicago, IL, June 1-5, 2018 and published in the congress proceedings (abstract 9021).
Methods: Six-hundred and sixteen patients were randomized to pembrolizumab 200 mg Q3W or placebo for 2 years; all patients received pemetrexed plus four cycles of carboplatin/cisplatin. EORTC QLQ-C30
and QLQ-LC13 were administered at cycles 1-5, then every three cycles during year 1, and every four cycles during years 2/3. Key PRO outcomes were changed from baseline to weeks 12 and 21 in the QLQ-C30 global health status/QoL score and time to deterioration in composite of cough/chest pain/dyspnoea. P values are nominal and twosided.
Results: Mean baseline scores were 61.98 and 60.56 in the pembrolizumab and placebo arms. At weeks 12 and 21, global health status/QoL scores were stable with pembrolizumab and decreased with placebo, with significantly greater decrement with placebo at week 21 (Table 1) . Median time to deterioration in composite of cough/chest pain/dyspnoea was NR with pembrolizumab (95% CI, 10.2 months-NR) versus 7.0 months (95% CI, 4.8-NR) with placebo (HR 0.81; 95% CI, 0.60-1.09; P = 0.081).
Conclusions:
In this trial, pembrolizumab+pemetrexed+platinum maintained or improved HRQoL over placebo+pemetrexed+platinum despite a higher grade 3-5 treatment-related AE rate. patients were more likely to be symptomatic (P < 0.001), have shorter PSA doubling time (P = 0.003) and tended to being younger (analysis across four age levels; P = 0.15). There was a significant transition away from WW to IST across the study period (P < 0.001), largely driven by the introduction of novel androgen receptor signalling inhibitors (ARSIs) in the first-line setting. Median time-to-treatment was statistically significantly different between years, H(3) = 20.127, P < 0.001.
Clinicians are performing less WW at the development of mCRPC, instead favouring earlier introduction of systemic therapy.
This trend is largely driven by the increased use of novel ARSIs as the initial treatment for mCRPC patients, coinciding with national regulatory approval of these medications. Results: One hundred and twenty-six patients from 10 oncologists at two sites participated. The median age was 72 years (range 65-84).
Predicting Chemotherapy Toxicity in
The median CARG Score was 7 (range 0-17), and the median oncologist estimate of risk was 30% (range 3-80%), and these measures were not correlated (r = -0.01). Sixty-four patients (52%) experienced grade ≥3 toxicity. Rates of severe toxicity in low-, intermediate-and high-risk groups by CARG Score were 58%, 47% and 58%, respectively, and 63%, 44% and 67% by oncologist estimate. Severe chemotherapy toxicity was not predicted well by the CARG Score (OR 1.04, 95% CI 0.92-1.18, P-value 0.54, AU-ROC 0.52), oncologists' estimates (OR 1.00, 95% CI 0.98-1.02, P-value 0.82, AU-ROC 0.52) or a model combining the two (AUC-ROC 0.52).
Conclusions:
The CARG Score, oncologists' estimates or a combination of the two were not good predictors of severe chemotherapy-related toxicity in our local population of older adults. Methods to improve risk prediction are needed. 
